BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25047669)

  • 21. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
    Pascual SI
    Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
    Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
    J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.
    Palmer RE; Amartino HM; Niizawa G; Blanco M; Pomponio RJ; Chamoles NA
    Neuromuscul Disord; 2007 Jan; 17(1):16-22. PubMed ID: 17056254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Two new mutations in the gene that codes for acid alpha-glucosidase in an adolescent with late-onset Pompe disease].
    Guevara-Campos J; Romeo-Villarroel MA; González-De Guevara L; Escobar V
    Rev Neurol; 2013 Sep; 57(6):265-8. PubMed ID: 24008937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for late-onset Pompe disease in Poland.
    Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A
    Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pompe disease: design, methodology, and early findings from the Pompe Registry.
    Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A
    Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy.
    Hossain MA; Miyajima T; Akiyama K; Eto Y
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.
    Chien YH; Chiang SC; Zhang XK; Keutzer J; Lee NC; Huang AC; Chen CA; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
    Pediatrics; 2008 Jul; 122(1):e39-45. PubMed ID: 18519449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots.
    Shigeto S; Katafuchi T; Okada Y; Nakamura K; Endo F; Okuyama T; Takeuchi H; Kroos MA; Verheijen FW; Reuser AJ; Okumiya T
    Mol Genet Metab; 2011 May; 103(1):12-7. PubMed ID: 21320792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
    Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
    Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease.
    Er TK; Chen CC; Chien YH; Liang WC; Kan TM; Jong YJ
    Clin Chim Acta; 2014 Feb; 429():18-25. PubMed ID: 24444888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
    Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
    Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population.
    Lee JH; Shin JH; Park HJ; Kim SZ; Jeon YM; Kim HK; Kim DS; Choi YC
    Neuromuscul Disord; 2017 Jun; 27(6):550-556. PubMed ID: 28433475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients.
    Momosaki K; Kido J; Yoshida S; Sugawara K; Miyamoto T; Inoue T; Okumiya T; Matsumoto S; Endo F; Hirose S; Nakamura K
    J Hum Genet; 2019 Aug; 64(8):741-755. PubMed ID: 31076647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.
    Laforêt P; Laloui K; Granger B; Hamroun D; Taouagh N; Hogrel JY; Orlikowski D; Bouhour F; Lacour A; Salort-Campana E; Penisson-Besnier I; Sacconi S; Zagnoli F; Chapon F; Eymard B; Desnuelle C; Pouget J;
    Rev Neurol (Paris); 2013; 169(8-9):595-602. PubMed ID: 24008051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program.
    Chiang SC; Hwu WL; Lee NC; Hsu LW; Chien YH
    Mol Genet Metab; 2012 Jul; 106(3):281-6. PubMed ID: 22578805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.